In a 6-6 vote, ODAC says “maybe” to Sutent for adjuvant kidney cancer—

But at FDA “Maybe” has meaning

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

With frustrating photo finish voting results—6-6—still on the screen, FDA’s cancer czar Richard Pazdur delivered an acerbic thank-you to members of the agency’s Oncologic Drugs Advisory Committee:

“Well, that’s the end vote, it makes our job definitely easier,” said Pazdur, director of the FDA’s Oncology Center of Excellence, who gets sarcastic sometimes.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

An updated version of President Trump’s budget request published on May 2 comes as a disappointment for those who hoped that the White House would rethink the draconian cuts contained in an earlier, confidential version of the document that ended up being leaked to the press. 
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login